Linked Life Data

20063133

Source:http://linkedlifedata.com/resource/pubmed/id/20063133

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20063133rdf:typepubmed:Citationlld:pubmed
pubmed-article:20063133lifeskim:mentionsumls-concept:C0032854lld:lifeskim
pubmed-article:20063133lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:20063133lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:20063133lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:20063133lifeskim:mentionsumls-concept:C0220615lld:lifeskim
pubmed-article:20063133lifeskim:mentionsumls-concept:C0205103lld:lifeskim
pubmed-article:20063133lifeskim:mentionsumls-concept:C1504389lld:lifeskim
pubmed-article:20063133lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:20063133lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:20063133lifeskim:mentionsumls-concept:C1561558lld:lifeskim
pubmed-article:20063133lifeskim:mentionsumls-concept:C1515895lld:lifeskim
pubmed-article:20063133pubmed:issue2lld:pubmed
pubmed-article:20063133pubmed:dateCreated2010-3-18lld:pubmed
pubmed-article:20063133pubmed:abstractTextWe prospectively compared allogeneic hematopoietic stem cell transplantation (allo-HSCT) with chemotherapy as a post-remission therapy in a multicenter trial (JALSG AML97) of adult patients with intermediate or poor risk acute myeloid leukemia (AML). Of 503 patients aged 15-50 years old registered between December 1997 and July 2001, 392 achieved complete remission (CR). CR patients classified in the intermediate or poor risk group using a new scoring system were tissue typed. Seventy-three with and 92 without an HLA-identical sibling were assigned to the donor and no-donor groups. Of 73 patients in the donor group, 38 (52%) received allo-HSCT during CR1 and 17 (23%) after relapse. Intention-to-treat analysis revealed that the relapse incidence was reduced in the donor group (52 vs. 77%; p = 0.008), and the disease-free survival (DFS) improved (39 vs. 19%; p = 0.016), but overall survival (OS) was not significantly different (46 vs. 29%; p = 0.088). The OS benefit was seen in the patients aged 36-50 years old (49 vs. 24%; p = 0.031), suggesting an advantage of allo-HSCT among older patients with leukemia that is more resistant to chemotherapy than that among younger patients.lld:pubmed
pubmed-article:20063133pubmed:languageenglld:pubmed
pubmed-article:20063133pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20063133pubmed:citationSubsetIMlld:pubmed
pubmed-article:20063133pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20063133pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20063133pubmed:statusMEDLINElld:pubmed
pubmed-article:20063133pubmed:monthMarlld:pubmed
pubmed-article:20063133pubmed:issn1865-3774lld:pubmed
pubmed-article:20063133pubmed:authorpubmed-author:YagasakiFumih...lld:pubmed
pubmed-article:20063133pubmed:authorpubmed-author:AsouNorioNlld:pubmed
pubmed-article:20063133pubmed:authorpubmed-author:MitaniKinukoKlld:pubmed
pubmed-article:20063133pubmed:authorpubmed-author:OhnoRyuzoRlld:pubmed
pubmed-article:20063133pubmed:authorpubmed-author:SakamakiHisas...lld:pubmed
pubmed-article:20063133pubmed:authorpubmed-author:OgawaYoshiaki...lld:pubmed
pubmed-article:20063133pubmed:authorpubmed-author:MiyawakiShuic...lld:pubmed
pubmed-article:20063133pubmed:authorpubmed-author:EmiNobuhikoNlld:pubmed
pubmed-article:20063133pubmed:authorpubmed-author:HondaSumihisa...lld:pubmed
pubmed-article:20063133pubmed:authorpubmed-author:KishimotoYuji...lld:pubmed
pubmed-article:20063133pubmed:authorpubmed-author:MiyazakiYasus...lld:pubmed
pubmed-article:20063133pubmed:authorpubmed-author:OhtakeShigeki...lld:pubmed
pubmed-article:20063133pubmed:authorpubmed-author:TakahashiMasa...lld:pubmed
pubmed-article:20063133pubmed:authorpubmed-author:MatsudaShinSlld:pubmed
pubmed-article:20063133pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20063133pubmed:volume91lld:pubmed
pubmed-article:20063133pubmed:ownerNLMlld:pubmed
pubmed-article:20063133pubmed:authorsCompleteYlld:pubmed
pubmed-article:20063133pubmed:pagination284-92lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:meshHeadingpubmed-meshheading:20063133...lld:pubmed
pubmed-article:20063133pubmed:year2010lld:pubmed
pubmed-article:20063133pubmed:articleTitleAllogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study.lld:pubmed
pubmed-article:20063133pubmed:affiliationDivision of Hematology, Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. sakamaki-h@cick.jplld:pubmed
pubmed-article:20063133pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20063133pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:20063133pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:20063133pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:20063133pubmed:publicationTypeMulticenter Studylld:pubmed